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Background: Despite its increasing prevalence and acceptance among the general public, cannabis use continues
to be viewed as an aberrant activity in many contexts. However, little is known about how stigma associated with
cannabis use affects individuals who use cannabis for therapeutic purposes (CTP) and what strategies these
individuals employ to manage associated stigma. The aim of this Canadian study was to describe users’ perceptions
of and responses to the stigma attached to using CTP.
Methods: Twenty-three individuals who were using CTP for a range of health problems took part in semi-
structured interviews. Transcribed data were analyzed using an inductive approach and comparative strategies to
explore participants’ perceptions of CTP and identify themes.
Results: Participant experiences of stigma were related to negative views of cannabis as a recreational drug, the
current criminal sanctions associated with cannabis use, and using cannabis in the context of stigmatizing
vulnerability (related to existing illness and disability). Strategies for managing the resulting stigma of using CTP
included: keeping CTP ‘undercover’; educating those who did not approve of or understand CTP use; and using
cannabis responsibly.
Conclusions: Understanding how individuals perceive and respond to stigma can inform the development of
strategies aimed at reducing stigma associated with the use of CTP and thereby address barriers faced by those
using this medicine.
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lighted the medical benefits of cannabis for diverse
health conditions [1,2]. In 2001, the Canadian govern-
ment officially created a medical cannabis programme to
authorize the possession, production and distribution of
cannabis for therapeutic purposes (CTP) for individuals
meeting specific criteria. Nevertheless, researchers report
that cannabis use continues to be viewed as aberrant
and CTP users experience stigma related to their use of
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reproduction in any medium, provided the orexperience related to CTP in order to provide a founda-
tion for developing strategies for reducing the stigma
and supporting CTP users in their use of this medicine.Background
Notwithstanding its current illegal status in Canada, can-
nabis has become the most widely used illicit drug and
its use is on the rise among most population groups [4].
In British Columbia, Canada, the setting of the current
research, over 50% of the population 15 years and older
have consumed cannabis at least once in their lives [5].
As a result, consuming cannabis has transitioned from a
once underground activity to one more openly accep-
ted by many. Public opinion continues to shift towards
the elimination or reduction of criminal penalties for
cannabis-related activities. However, those who conti-
nue to believe these activities should be penalized are
increasingly more likely to hold favourable attitudesLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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benefits [6,7]. Despite these changes in public attitudes
towards cannabis, users continue to experience a certain
level of stigma and risk in their use of CTP, particularly
from authorities such as employers, landlords, and law
enforcement [3,8]. Specific civic norms and etiquette
are often employed by users in public spaces to avoid
drawing attention to their cannabis use. Even with
the establishment of Health Canada’s Canada Medical
Marihuana Access Regulations (MMAR) in 2001 stigma
against CTP users remains an issue [9]. Little is known
about how the stigmatization of cannabis use influences
therapeutic users’ patterns of use and their personal
lives, and in-depth explorations of the strategies they
employ to manage these experiences are limited.
Stigma, health and CTP
Goffman’s (1963) ground breaking work on stigma
underpins our understanding of health-related stigma
[10]. In this work, he defines stigma as: “The pheno-
menon whereby an individual with an attribute which is
deeply discredited by his/her society is rejected as a re-
sult of the attribute” (p.21) and argues that stigma is an
interactional process that “spoils identity.” As such,
people who are perceived by others to deviate physically
and behaviourally from social norms and values are sub-
ject to disapproval, and marginalization, and often ex-
perience discrimination and loss of status. These social
interactions can result in enacted stigma (i.e., external
stigma) when others’ judgements about difference are
translated into rejection, distancing and other discrim-
inatory practices; as well as perceived stigma (i.e.,
internal stigma) wherein individuals’ assumptions or
fears of discrimination lead to self-perceptions of shame
and guilt, and protective action such as self-imposed
isolation.
Efforts to use and refine the concept of stigma for
public health have been prompted by observations of the
profound negative health effects of the social disqualifi-
cation of individuals and groups who are identified with
particular diseases or disorders [11,12]. For example,
disease-related stigma in the context of mental health
problems highlight the significant deleterious effect of
stigma on health and well-being when individuals avoid
health care or seeking other forms of support because of
feelings of shame or embarrassment.
As chronically ill individuals and illicit drug users,
CTP users are at a high risk of experiencing multiple
sources of stigma from various fronts [13]. A diagnosis
of chronic illness that is either visible (e.g., multiple
sclerosis, and epilepsy) or relatively invisible (e.g., HIV/
AIDS, fibromyalgia, and mental illness) often results in
stigma and social isolation [14-17]. Although substance
use is associated with varying degrees of stigma, illicitdrug users are among the most stigmatized groups
[18,19]. Beyond the stigma of being labelled a drug user,
the additional stigma of being formally charged as a
criminal can also have lasting negative effects. Social
disqualifications targeting other features of a person's
identity (e.g., poverty, gender, sexual orientation) can
compound these experiences of stigma [20,21]. An
understanding of the experiences of stigma among CTP
users is, therefore, important and relevant to the health
services provided to these individuals.
Social and legal consequences of using CTP
While studies that investigate the experiences and
concerns of recreational cannabis users are common,
CTP remains poorly understood. A Canadian study of
current HIV/AIDS CTP users reported many CTP users
were met with “laughter, scepticism, or with negative
reactions” (p. 41) from non-users for their CTP use [22].
They felt stigmatized for their choice of therapy both by
their “healthy” peers and the medical system in general.
Becoming licensed users through the MMAD Health
Canada program helped alleviate some of the related
stress and perceived stigma of CTP use and empowered
them to improve their overall health. Other authors have
reported that social and legal concerns motivated some
individuals to conceal their CTP use and avoid disclos-
ure beyond immediate family members [23]. When CTP
users met with disapproval from family members, they
reported it was often based on concern over the legal
implications of CTP use and the potential of negative
health effects and addiction.
The negative social implications of using CTP have also
been observed elsewhere. A California-based study of
pregnant women suffering from Hyperemesis Gravidarum
(a highly debilitating pre-partum illness characterized by
severe nausea, vomiting, malnutrition and weight loss)
found that for participants, cannabis was their best option
when traditional treatments were ineffective and, at times,
traumatic [24]. Being pregnant and using cannabis, how-
ever, put participants at high risk for stigmatization. They
were often belittled and declared deviant by their peers
and the medical community for their decision to use CTP.
Additionally, while these women were open and successful
in using cannabis to treat extreme symptoms, they con-
tinued to experience strong feelings of anxiety, guilt and
fear over CTP use. As Canadian CTP regulations are now
over a decade old, it is timely that research be conducted
examining the social context of CTP use and the influence
of stigma on CTP users’ lives. The specific research
questions guiding this study were: 1) What are CTP users’
experiences of stigma? and 2) What strategies do CTP
users employ to negotiate their experiences of stigma? By
understanding how individuals perceive the potential so-
cial implications of CTP use, new approaches can be
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support individuals using CTP cope with stigma.
Methods
This research employed a qualitative descriptive design
[25] and drew on the tenets of naturalistic inquiry [26] –
a method recognised as particularly useful when investi-
gating vulnerable persons with health disparities [27].
Using qualitative methods, inductive analysis and pur-
posive sampling, we developed an in-depth account of
the experiences of CTP users.
Study setting
This study was conducted in Canada, where the use of
CTP is directly shaped by the federal laws governing what
is considered to be a controlled substance. Cannabis pro-
duction, distribution and possession remain illegal in
Canada, with the exception of Health Canada’s licensing
program for therapeutic users, the Medical Marihuana
Access Program (MMAP). Since the MMAP’s formation
in 2001, those persons wishing to legally possess and ob-
tain CTP must apply for a license directly to Health
Canada, which acts as the governing body that oversees
the implementation of the Medical Marihuana Access
Regulations (MMAR). Paradoxically, Health Canada con-
tinues to state that “marihuana [sic] is not an approved
therapeutic product” [28]. Ostensibly mixed messages,
such as this policy statement, along with public health
strategies directed towards reducing cannabis use (e.g., the
National Anti-drug Strategy), has complicated the context
within which individuals use CTP. Although the establish-
ment of the MMAP has been seen as a step forward by
some groups [29-31], others have expressed reservations
about the program [9,32,33] pointing to access issues, the
complexity of the application forms and the length of time
required to process applications [9]. Apprehension about
the quality, potency, and lack of quality control and strain
selection of MMAD-supplied cannabis also continues
to be a source of controversy for many CTP users [9].
Concerns about access have resulted in a recent court de-
cision in Canada that has found the MMAR to be “consti-
tutionally invalid and of no force and effect” [34], forcing
Health Canada to engage in a community consultation
process to discuss potential changes to the regulations and
programme.
The need for safe and informed access to cannabis has
been central to the development of community-based
dispensaries (i.e., compassion clubs) in Canada. The dis-
pensaries provide illegal, high quality cannabis to their
members (who must have medical documentation of an
approved medical condition) as well as information
regarding CTP to assist with making decisions about
cannabis use. The dispensaries reduce the risk of legal
repercussions associated with accessing illegal cannabisby providing a safe environment for members to pur-
chase CTP and by acting as members’ social and legal
advocates [35]. Although access to CTP through dis-
pensaries is a form of civil disobedience, many law en-
forcement officers and courts recognize identification
cards from these dispensaries as adequate proof of legit-
imate CTP use, giving discharges to verified members
and to dispensary operators who manage their clubs in a
transparent and responsible manner [35].
Recruitment and sampling
Following university ethical approval, purposive sam-
pling was used to recruit current CTP users through
four British Columbia community-based cannabis dis-
pensaries as well as through a Canadian online forum of
CTP users in 2007–2008. Eligibility criteria required
participants to: a) report using CTP in the last 30 days
and for over 6 consecutive months, b) be at least 19 years
of age, and c) speak English. In accordance with ethical
requirements and to protect individual identities, all
participants reviewed the consent form and were asked
to give their consent verbally on tape at the start of the
interview. No record of participants’ names or identify-
ing characteristics was kept and all participants received
a C$25 honorarium for their time.
The sample comprised 23 participants (13 women, 10
men). Two transgendered (male to female) participants
were included in the women’s subgroup. Participants
ranged in age from 25 to 66 years (mean = 45 years) and
had an average annual income of $21,000, slightly below
Canada’s 2008 low income cut-off for individuals living
in a large urban area ([36], p.25). Approximately 78%
were either single or divorced/separated and over two
thirds had completed at least some university or college.
Most participants were engaged in paid work (52%) or
caring for a family member (39%). HIV/AIDS was the
most commonly reported disorder for which CTP was
used (6 participants), followed by fibromyalgia (n = 5),
arthritis (n = 4), mood/anxiety disorders (n = 3), cancer
(n = 2), neurological disorders (n = 2), gender dysphoria
(n = 2) and other disorders (n = 4). Some individuals
were living with multiple diagnoses. Participants
described their CTP use as long-term (mean = 8.3 years,
range = 2 to 16 years). All participants smoked CTP; 15
indicated they also ingested it and nine used a vaporizer.
Other methods used by participants included tinctures
(n = 5), sprays (n = 2), cannabis mixed with tobacco (n =
1) and use of a poultice (cannabis mixed with alcohol
and applied topically) (n = 1). When asked about their
purchase locations, only five of the eleven participants
that currently held a Health Canada license indicated
they purchased their cannabis from Health Canada and
most (n = 20) purchased it from a community-based dis-
pensary. Participants also indicated they accessed CTP
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licensed growers (n = 10).
Data collection
Data were collected using semi-structured, individual
face-to-face or telephone interviews. Participants were
invited to discuss their beliefs about and experiences of
using CTP and their experiences of stigma. At a time
and location convenient to the participant, interviews
were conducted by trained research assistants and lasted
approximately 1–3 hours. A short questionnaire was
administered to gather demographic data, history of can-
nabis use, and information about health issues influen-
cing use of CTP.
Data analysis
Using an inductive thematic approach to data analysis,
interview transcripts were read and re-read by the
authors and sections of the data that reflected emergent
ideas and themes were highlighted. In investigative team
meetings, independent reviews of the data were
summated and shared to reach consensus about categor-
ies for coding the data. The qualitative data management
software program, NVivo™, was used to organize the
data for retrieval and in-depth analysis. Comparative
strategies were used to explore participants’ perceptions
of CTP.
Results
Participants’ narratives included a predominant discourse
of stigma associated with CTP use. Experiences of stigma
arose in interactions with family members and close
friends, as well as from others in society. The multiple
dimensions of stigma associated with using CTP use iden-
tified in the data afforded a view of participants’ ex-
periences whereby most contributed to more than one
dimension. In order to achieve the benefits of cannabis
use, participants had to negotiate social censorship, disap-
proval, threats, and isolation. Ways participants coped
with and minimized their experiences of stigma associated
with CTP use are also described.
Dimensions of stigma associated with CTP
Three dimensions of stigma were identified that related
to negative views of cannabis as a recreational drug, il-
legal activity surrounding cannabis use, and layered vul-
nerabilities related to poverty and particular illnesses
and disabilities. Each dimension is described in the
following sections.
Medicine in a joint
Unlike other medications the participants used, CTP was
more difficult to conceal particularly when consumed
through smoking. The distinctive and often times strongsmell, appearance, and behaviours associated with smok-
ing a joint invoke negative images for some, such as the
“pothead,” and have been reinforced by the media and
public opinion. We use the word “joint” deliberately to
highlight the stigma participants’ experienced. Dominant
views of cannabis, as a recreational drug used for pleasure,
to just “get high” and to escape the realities of life were
perceived to make it difficult for the medicinal value of
cannabis to be recognized and defended in an objective
way. As a consequence, participants reported being la-
belled as “potheads” by their families, healthcare providers
and society at large. Some were falsely accused of using
CTP not for medicinal purposes but “just to have some
fun” (woman, aged 45, digestive disorder). These labels
positioned CTP users as irresponsible, non-contributing,
and on the margins of society, unbecoming attributions
participants refuted. One man (aged 45, fibromyalgia)
resented “being perceived as something less than accept-
able” and felt that he was unfairly judged by others specif-
ically because of his use of CTP:
Nobody turns around and says you’re a junkie if you
have terminal cancer and are on heroin. But it doesn’t
matter why you’re on marijuana, [if] you’re on
marijuana, “You’re a pothead and get the hell away
from me.”
In this example, the man reveals a comparison point
whereby harder drugs such as heroin can be packaged as
therapeutic and legitimate in the context of buffering
the symptoms that accompany advanced disease when
there is little hope of survival. Yet, cannabis is not
understood as affording the same relief – rather, its use
brings into question both the legitimacy of the illness
and the role of smoked cannabis as a medicine.
Constructions of cannabis as an addictive substance
were also perceived to contribute to condemnations of
its use as a medicinal drug of choice, and thereby
stigmatized users. Users of CTP reported being labelled
“drug addicts” and that others, including physicians,
continually reminded users that cannabis was a “bad
medicine” that could lead to addiction. Even when
participants were prescribed other potentially addictive
medications (e.g., oxycotin, sleeping pills), it was their
use of cannabis that was scrutinized and criticized.
Healthcare providers went as far as to offer participants
counselling to “get help” with their assumed marijuana
addiction.
External stigma was also reflected in the lack of trust
expressed by family members as well as health
professionals as a result of participants’ use of CTP.
Participants reported not being believed by others when
they described the medical benefits they experienced
from cannabis and their requests for cannabis led to a
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Participants recounted that others thought they were
“making things up,” “faking things” or “manipulating
symptoms” to get safe access to cannabis. There was an
underlying sense that participants were viewed as being
unreliable, dangerous, unsavoury, and “abusing the sys-
tem” when in fact, they believed they were attempting to
resolve the health problems they experienced in a re-
sponsible way.
Perceptions that cannabis use “changed” people and
interfered with their ability to think clearly and act re-
sponsibly also contributed to the stigmatization that
CTP users experienced. Participants reported to be re-
luctant to tell their employers or coworkers of their CTP
use, fearing that they would lose their professional sta-
tus, and they and their work performance would be
negatively judged.
In summary, there was consensus that the stigma
associated with cannabis use negatively impacted
participants’ social, professional and family ties as well as
their relationships with healthcare providers. These
reactions forced participants to self-regulate and with-
draw from some of their social networks and resulted in
social isolation, estrangement from family and friends,
and for some, relocation to another city. The reactions
also acted as a barrier to receiving the health care many
participants needed.
Medicine on the wrong side of the law
Cannabis as a stigmatized medicine was also confounded
with the fact that it is an illegal substance. Users of CTP,
therefore, explained they were faced with not only being
labelled as “potheads” but also criminals. They reported
being viewed with suspicion and marginalized for their
illegal activities associated with using CTP. One woman
(aged 45, digestive disorder) indicated that she was ini-
tially hesitant to begin using CTP because of the stigma
associated with cannabis as an illegal substance:
When I first came to the compassion club it was an
emotional thing for me, I cried when l left. I was like,
“Oh my God, this is where my life has thrown me?
I’ve lost my career. I’m in the ditch vomiting. Now
this is what I have come to”. I was like, “It’s illegal! It’s
illegal!” I want to be an upstanding citizen; I don’t
want to be a criminal. But then, as I was realizing a
little clearer what was really going on, I realized it was
the biggest gift and my complete ally and then my
whole concept just shifted.
Having a federal license or community-based dispens-
ary membership card provided recognition of their need
for medical cannabis and thus distinguished users of
CTP from illegal recreational users. However, for someholding a license or membership card did not negate the
stigma they experienced as CTP users because they felt
“branded” as being involved in an apparently illegal ac-
tivity, and described additional scrutiny and differential
treatment that negatively impacted their lives. For ex-
ample, a 55-year-old woman thought her fears would be
relieved upon receiving her license from Health Canada,
but instead felt much regret over the process and
believed she was in a worse situation:
I thought I’d feel different but I don’t. . . I don’t feel as
safe now because I’ve identified myself as a pot
smoker where before I was anonymous and I think I
was in a better position. . . If I had to do it over again
I wouldn’t even tell my doctor, it wasn’t worth it.
Similarly, a 27-year-old man with cancer believed that
since receiving his Health Canada licence, he was
“discriminated upon constantly” by police who would
often detain him until they verified the legitimacy of his
license:
It’s all fun and games the first 10 times you do it but
after, you know, you get pretty annoyed. I mean if I
just had to flip them a card and walk away then that
would be a little different but they’ve got to run your
name. They’ve never heard of the program, they want
to have it explained to them or if they have heard [of
the MMAD], you know, I’ve literally had cops make
me wait while they bring a couple of other cops over
to look at the licence.
The inclination that those producing their own CTP
might be dealers was also a site for stigma. Despite
being “legal,” those that cultivated their own cannabis
with licences were often harassed by local police,
landlords and subsidised housing investigators. Several
had been subjected to what they believed were unwar-
ranted raids on their property and would often lose their
cannabis plants in the process either due to confiscation
by the police or by their own hand to conceal their
gardens. One 36-year-old woman living with AIDS was
repeatedly harassed by the police who were supposed to
be checking the security of her residence. They wanted
to see her garden and questioned the validity of her fed-
eral licence. Legal producers also had difficulty finding
and keeping their housing due to landlords’ concerns
about the legitimacy and impact on other tenants of
their cultivation of cannabis. One participant, a man liv-
ing with AIDS in a subsidised housing residence,
complained that he was constantly investigated by the
housing officials. He often dismantled his garden to
avoid confrontation and to keep his lease despite the
loss of his home-grown medicine.
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with cannabis, participants believed their CTP use also
raised suspicions and judgements about their ability to
parent. Several participants feared losing custody of, or
access to, their children as a result of being caught with
CTP. One user of CTP (aged 34, AIDS) resented this,
stating people “shouldn’t have to fear [their] kid being
taken away because of [their] choice in medicine.” Being
a parent, therefore, led participants to take steps to con-
ceal their use of CTP.
Using cannabis in the context of layered vulnerabilities
For many participants, the stigmatization they expe-
rienced in using cannabis was entangled with other
stigmatized vulnerabilities, such as living with a mar-
ginalized disorder (e.g., HIV/AIDS, fibromyalgia, mental
illness, history of drug addiction), transitioning gen-
der identity, being homosexual, or living in poverty. A
34-year-old man who held a federal licence, talked about
the multiple stigmas he lived with which made his can-
nabis use less acceptable than that of others who did not
have AIDS or a history of drug addiction:
It doesn’t matter how many federal licences [I have]. . .
I’ve got the stigma of AIDS, I’ve got the stigma of an
ex-junkie, okay, so I’ve got a lot of dirt in my closet that
can be thrown up, right. But if one of [my brother’s]
friends who don’t have this dirt, if one of those friends
suddenly started smoking cannabis and he got a federal
licence like me, I think it would be a little more
accepted.
In this example, the man’s history of addiction prevails
and the remnants of his past drug use (i.e., HIV/AIDS)
locate CTP as little more than a new addiction. These
vulnerabilities created challenges in accessing CTP.
Requests for CTP were often questioned or not taken
seriously on the basis of already suspect diagnosis and
practices, and frequently resulted in long delays in
accessing CTP. Other individuals who had struggled for
years to get diagnosed or be referred to specialists had
difficulty generating enough energy to lobby or negotiate
access to CTP when healthcare providers had already la-
belled them “problem” patients or held judgemental
attitudes about their illnesses.
Coping with stigma associated with CTP use
Choosing to continue their use of CTP because of the
significant benefits experienced in relation to managing
their health problems, participants engaged in a variety
of coping strategies to respond to the stigma associated
with CTP use. Strategies identified in this data were:
keeping use of CTP undercover, convincing others of
the benefits of CTP, being responsible in their use ofCTP and actively defending their right to choose their
own medication.
Covert use: keeping CTP use undercover
Some participants believed that with the overwhelming
condemnation attributed to cannabis and the current
criminal sanctions associated with cannabis in Canada,
there was little they could do except be covert in their
CTP use. As such, they guarded and hid their use of
cannabis from others. When one 55-year-old woman
was asked if she had any advice for other CTP users, she
stated: “Keep your mouth shut, grow it, use it, don’t tell
anybody, don’t even tell your family, don’t tell your
friends, keep it to yourself and save your own life.”
Individuals went to great length to cover up their CTP
use, including lighting incense to mask the smell, smok-
ing away from their home, changing their clothes after
smoking cannabis, and being vigilant about who was
around when they smoked.
By using CTP covertly, participants also protected
themselves through self-imposed social isolation. Some
isolated themselves in order to avoid criticism and
feeling “guilty” about their use. Others smoked in private
to avoid children seeing them smoke cannabis. One
woman who isolated herself from her family explained:
I have a very difficult time convincing my family why
I have to use it and it’s just got to the point where I
don’t even bother talking to my family because of the
fact that they just keep dissing me because I use it....
They’re old school, a drug’s a drug, that’s their
mentality.
Expert use: convincing others of the benefits of CTP use
Several participants believed that the harsh judgemental
attitudes they had experienced were the result of “misin-
formation” from the media and a general lack of know-
ledge of CTP. As such, several participants believed that
the only way to address this was to educate and discuss
the therapeutic properties of cannabis “to open other
people’s eyes.” One man (aged 42, daily user, AIDS)
argued that if the perception of cannabis was to change
to being a therapeutic agent rather than a recreational
drug, much would be improved:
It’s that stigma attached to pot, that lovely word pot
has such a bad condemnation to it. Meanwhile people
can pop sleeping pills left, right and center and
nobody thinks anything of it. So it’s a perception.
When we can change that perception of what this is
and what the approach is [cannabis as therapy], the
battle is half won. [It would help for] people to talk
about the issue, get proper information out there, and
if you can stack the seats with informed people and
Bottorff et al. Harm Reduction Journal 2013, 10:2 Page 7 of 10
http://www.harmreductionjournal.com/content/10/1/2reach out to a community where you need to reach
out to, then you can start the process.
The work of informing friends and family was often a
long (but important) process of education on the part of
participants. A 36-year-old woman’s experience with her
mother typified this experience:
She [participant’s mother] goes, “I think you have a
problem, I think you have an addiction.” Now I
looked at her and said “I’m not taking really any pain
killers at all, okay, nothing, I’ve taken myself off
prednisone, taken myself off the [mesalamine], not
taking [acetaminophen/codeine], and you’re telling
me, Mother, I’m possibly addicted to cannabis?” We
had a slight fight about it [laughing] and then, of
course, she changed her mind because I had to
educate her, as well as many others, and now she
doesn’t like to admit to that little story because now
she is a full on cannabis granny, raging granny. I
mean she is so supportive. Now she looks at me and
she is very, very proud. She doesn’t feel I have an
addiction problem in any way.Responsible use: doing everything “right”
In an effort to reinforce the differences between recre-
ational and therapeutic uses of cannabis, some participants
cast aspersions on recreational users while exulting them-
selves as being a responsible user and “clean on other
fronts” (aged 43, daily user, Fibromyalgia). For example,
when asked how her therapeutic use compared to recre-
ational users, one woman (aged 36, licensed user, HIV-
AIDS) asserted, “They act stupid some of them. . .because
they flaunt it, they’ll smoke it anywhere.” In contrast and
as a “responsible” CTP user, she took precautions and al-
ways smoked with discretion: “I don’t flaunt it, like sit there
with my arm out the window.” She identified recreational
users as “pimps, pushers and, people in the criminal world”
and stated they were “different” from her. A 36-year-old
man (daily user, chronic back pain) believed therapeutic
use was fundamentally different because “recreational
people are the people who use it and giggle and laugh and
joke around and then that’s it.” Participants perceived their
use of CTP as “necessary” while recreational use was often
strictly “social” in nature. A third participant (aged 36, daily
user, HIV/AIDS) who indicated she never used cannabis
recreationally stated: “I think the recreational is more for
relaxation not for pain, what it’s supposed to be for, it’s
more for them to party with. For us, it’s more of a life
thing.” As a result of the necessity of their use of CTP,
participants were very particular in how they procured
their cannabis, how much they used, and when so as not
to be confused with recreational drug addicts.Leading by example was what one participant (aged
42, daily user, HIV/AIDS) believed he could do to
change society’s perceptions of him and his CTP use.
And while he was fully aware that he would not be able
to change opinions overnight, he remained hopeful and
believed that once others saw him as a responsible user,
their attitudes towards him and CTP would start to
change:
I can only do what I can do for myself and present
myself and approach my life in the way that shows
that I am not a drug addict. I am not a detriment to
society. I’m actually trying to be a part of society but I
am kind of running into a lot of roadblocks. I know
how the world works. It happens slowly, very slowly
and usually it’s one or two or three people who start
and take it somewhere and then other people build on
it. That’s all you can do.
Participants also attempted to control the stigma
surrounding their use of CTP by being open and honest
about their use. Applying for a federally-issued licence
for CTP use and production, and notifying law enforce-
ment of their CTP production were ways some
participants attempted to manage their image as a re-
sponsible cannabis user.
Activist use: CTP as a human rights issue
Notwithstanding the stigma experienced for using an il-
legal substance therapeutically, participants continued to
staunchly defend their right to choose their own medica-
tion. And despite “swimming [in a] pool with sharks”
and illegally accessing CTP, many participants were
committed to using CTP and helping others gain access
regardless of the potential risks, including arrest and/or
imprisonment. Several participants became activists in
their own right and argued that neither the government
nor the medical community had the right to deny them
access to their “medication”, or to persecute them for
using it. Doing what he felt was “logically and ethically
correct in [his] heart”, one 34-year-old man living with
AIDS dared the government to take away his CTP:
Screw them, I’m a free man, you know? Furthermore,
I’m [now] like a 60 or 70 year old man. I’m living out
my final years. Do you really think I’m going to listen
to some federal regulation for Christ’s sake? I mean
this is insane.
Similarly, other participants believed it was the duty
and “moral ethical obligation” of Health Canada to ex-
plore the therapeutic uses of cannabis and to “open up
access in order to maximize the benefits of medical can-
nabis in society as a whole”. Some were hopeful that
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eventually change and they would be able to use their
medication freely and openly without fear of prosecution
(woman aged 36, daily user, AIDS):
I will get the message across, because I know it’s
coming. Yeah, freedom is a right. I hope this all goes
through finally [and] that we shouldn’t have to go to
jail for what we believe in, for helping sick people. I
don’t believe it’s a crime and I believe it’s a waste of
taxpayer’s money, and the government should stay out
of it. This should be a medical, a medical thing and
that’s it.
Discussion
Stigmatization as a form of social control which func-
tions to discourage and penalize deviant behaviour,
characteristics or identities was reflected in the findings.
The findings suggest there are complex and overlapping
factors that produce both the stigmatization experienced
by CTP users that related to the ambiguous status of
cannabis, lack of acknowledge about medical cannabis,
and stigma associated with particular health disorders.
While public acceptance of cannabis continues to grow,
it appears that CTP users remain highly vulnerable to
stigma at both interpersonal and institutional levels.
Participant experiences of stigma related to CTP use
stemmed from external sources, including their friends,
family, healthcare providers, and law enforcement, and
from their own internalized guilt and discomfort related
to using a medication that is also often used recreation-
ally and illegally. In addition, victim blaming discourse
was evident, whereby the illness for which CTP was used
attracted harsh judgements about the person’s previous
health practices (e.g., HIV/AIDS in homosexual and IV
drug users, smokers who get cancer) and the validity of
their treatment requests. Suspicion about previous risky
behaviours was prompted by CTP use and interpreted as
emerging from irresponsible acts and disregard for self-
health. In addition, illnesses for which others adjust or
adequately cope with using conventional medical treat-
ments, rendered suspect the use of CTP as a legitimate
course of treatment.
Stigmatization related to cannabis as a substance and
its illegal status are clearly intertwined. Historically, can-
nabis was made illegal not because of problems asso-
ciated with its use, but rather, as a result of propaganda
that encouraged the public to view cannabis as risky and
untoward in order to reify its criminal classification [37].
Engaging in illegal activities, more generally, is stig-
matized in society. Criminalizing activities render them
deviant, and it is generally assumed within society that
there is a good reason for this status. Even though devi-
ance and criminality were not central to the majority ofparticipants’ self concepts, “disidentifiers” [10] were com-
monly used to distance themselves from these labels. For
these individuals who were already living with a chronic,
often life-limiting illness and on the margins of society,
this additional form of stigmatization increased the phys-
ical and emotional distress they experienced.
Even more problematic from a human rights perspec-
tive is the potential for discrimination in the healthcare
system, where individuals fail to receive appropriate as-
sessment and treatment for a health condition because
of being labeled as drug dependent or a pothead. In this
context, patient-provider consultations become focused
on extraneous issues, such as addiction and one’s moral
fiber, rather than the larger concerns of symptom man-
agement and the underlying pathology of illness. Amid
this preoccupation resides an uneasiness and lingering
doubt that CTP use is contrived and manipulative,
whereby cannabis is masking, and in many cases adding
to, the individual’s and societal problems. This discourse
threatens the trust essential for a caring patient-provider
relationship and may disrupt future care-seeking behav-
iour by patients as well as the delivery of efficacious
treatments by healthcare providers. Physicians, in par-
ticular, have the obligation and duty to provide safe,
competent, and ethical care to all individuals in accord-
ance with current and accepted standards of prac-
tice [38]. Although CTP remains in the hinterland of
accepted standards of practice within North America,
the growing body of evidence supporting its use as a
medical treatment and its availability through an
established federal health program is forcing the hand of
physicians and other healthcare providers to consider
the potential value of cannabis as a therapeutic agent.
To not do so could be potentially viewed as a breach in
care and a discriminatory action.
The Supreme Court of Canada recognized that it is
constitutionally problematic to put people in a position
to have to choose between their liberty and their health,
and this led to the establishment of the federal medical
cannabis programme [39,40]. And while there continue
to be advancements in the rights of CTP users at the ju-
dicial level, they are often on a case by case basis, and
incidents of discrimination continue to be documented
and arrests are common [41,42]. All participants in this
study were either MMAD licence holders or medical
cannabis dispensary members, meaning that their use of
CTP was legitimate (i.e., it was for a documented med-
ical condition). However, only those with MMAD
licences who procured CTP from Canada’s contracted
producer were using CTP legally. For some, choosing
the legal government route was a way to quell their in-
ternal concerns about acting lawfully. However, it was
apparent from our interviews that this did not necessar-
ily relieve external stigma. Outing themselves as CTP
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ally found themselves facing more external stigma than
if they had been hiding their use. It appears that due to
the overarching illegal status of cannabis outside of the
narrow exception for therapeutic use, the legal route
does not necessarily alleviate stigma for CTP users.
Although the use of CTP appeared to be a marker of in-
dividual expression or identity, not unlike some recre-
ational users experiencing stigma, fear of shame and loss of
status necessitated efforts to manage stigma. Management
of personal information and others’ knowledge of CTP use
appear to be of critical importance to CTP users, with
many choosing between hiding their use from others in
order to pass as normal to avoid sanctions (i.e., social
avoidance) or being open about it (selective or indiscrimin-
ate disclosure) in an attempt to inform others about CTP
and assist with redefining users as “normal” law-abiding
citizens [43]. These reactions are common in the stigma lit-
erature and both serve as an attempt to protect oneself
from further stigma [44,45]. Study participants’ efforts to
be responsible and discrete in their CTP use to avoid
drawing attention (particularly from law enforcement) are
similar to those observed among both therapeutic and rec-
reational cannabis users [3,23,46]. The fact that some
participants chose to be open about their CTP use may re-
flect established coping strategies developed in response to
long-standing stigmatizing illnesses.
While many study participants took it upon them-
selves to educate others about the value of cannabis as a
medicine, it is unrealistic that the work of stigma reduc-
tion rest solely on individuals compromised by health
problems. Instead, formal education programs and policy
reform is required that targets healthcare providers, law
enforcement personnel, government authorities, as well
as members of general society. Interventions that ad-
dress the history of cannabis criminalization, as well as
the legitimacy of CTP use and the options for legal CTP
use, would go a long way to ensuring CTP users experi-
ence the full spirit of their constitutional right to health
without fearing legal repercussions or experiencing the
stigma of being associated with an illegal activity. Such
programs could be modelled after other successful
stigma reduction interventions that have been developed
for other marginalized groups, including HIV/AIDS and
mental illness [47-49].
Several limitations to this research are recognized.
Participants were from British Columbia, a Canadian
province known for its illegal cannabis production and tol-
erance of recreational use. The contradictions experienced
by the CTP users in this study cannot be understood apart
from the social and structural conditions that influenced
how users viewed themselves and how they are viewed by
others. Experiences of and reactions to using CTP may
have differed if participants had been recruited from moreconservative regions. As most of the participants indicated
they were long-term users and had made the decision to
use CTP several years before, their experiences of stigma
may not be the same as those who have just begun to use
CTP. Furthermore, the participants were self-selected (i.e.,
they were willing to speak openly about CTP). As a result,
it could be that those who had experienced more negative
stigma while using CTP, those who no longer used CTP
for fear of its social and legal ramifications or who did not
want to be a magnet for their friends’ or families’ discon-
tent were thus likely underrepresented in this study.
Further research is required to examine how experiences
of stigma evolve over the course of CTP treatment
and among different populations in different legal/social
climates.
Conclusion
Experiences of stigma among those with illness and the
role stigma plays in seeking treatment are not new in
the literature. However, in this literature it is not neces-
sarily the treatment that is stigmatized, but the illness
for which the treatment is used. CTP stands as one of
the few treatments where users are directly stigmatized
for their use of it regardless of their particular illness.
The findings of this study shed light on how individuals
using CTP experience stigma, and the effect on their
physical and emotional wellbeing as well as the impact
on healthcare interactions. The stigmatization of CTP
users is related to the ambiguous status of cannabis (an
illegal substance and a legal therapeutic agent at the
same time), and to the lack of acknowledge about med-
ical cannabis among the public, physicians, and law en-
forcement personnel. The findings reinforce the urgent
need for finding better solutions and strategies to reduce
stigmatization associated with use of CTP.
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